Buyback Spend for Quest Diagnostics (DGX)
Buyback Spend for Quest Diagnostics (DGX): headline value $450.00M · YoY +198.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingBuyback SpendSwitch metric
Latest period
$450.00M
YoY change
+198.0%
5Y CAGR
+6.7%
Peak year (2021)
$2.20B
Latest annual
$450.00M
Buyback Spend history chart for Quest Diagnostics (DGX) from 1996 to 2025
Buyback Spend history table for Quest Diagnostics (DGX) from 1996 to 2025
| Fiscal year | Period ended | Reported | Buyback Spend | YoY |
|---|---|---|---|---|
| 2025 | $450.00M | +198.0% | ||
| 2024 | $151.00M | -45.1% | ||
| 2023 | $275.00M | -80.5% | ||
| 2022 | $1.41B | -36.0% | ||
| 2021 | $2.20B | +576.6% | ||
| 2020 | $325.00M | -7.9% | ||
| 2019 | $353.00M | +9.6% | ||
| 2018 | $322.00M | -30.8% | ||
| 2017 | $465.00M | -21.2% | ||
| 2016 | $590.00M | +163.4% | ||
| 2015 | $224.00M | +69.7% | ||
| 2014 | $132.00M | -87.3% | ||
| 2013 | $1.04B | +418.5% | ||
| 2012 | $200.00M | -78.6% | ||
| 2011 | $935.00M | +24.7% | ||
| 2010 | $750.00M | +50.0% | ||
| 2009 | $499.99M | +96.8% | ||
| 2008 | $254.00M | +74.4% | ||
| 2007 | $145.66M | -69.2% | ||
| 2006 | $472.32M | +21.1% | ||
| 2005 | $390.16M | -46.9% | ||
| 2004 | $734.58M | +185.2% | ||
| 2003 | $257.55M | — | ||
| 2002 | $0 | -100.0% | ||
| 2001 | $1.00M | — | ||
| 2000 | $0 | -100.0% | ||
| 1999 | $1.10M | -91.5% | ||
| 1998 | $13.00M | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — |
Buyback Spend values are taken from Quest Diagnostics's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Quest Diagnostics (DGX) most recent annual buyback spend stands at $450.00M (2025) – surged 198.0% year-over-year.
Quest Diagnostics buyback spend compound annual growth for the 2020–2025 (5 years) window is +6.7%, with the latest reading among the more recent periods of the dataset.
Quest Diagnostics buyback spend peaked at $2.20B in 2021; the latest annual figure is $450.00M in 2025 (79.5% below peak).
The dataset's maximum buyback spend sits at $2.20B (2021); the minimum reading of $0 dates to 1996.
Among 8 Healthcare peers, Quest Diagnostics (DGX) ranks 8th; the peer median for buyback spend is $2.75B.
Quest Diagnostics Buyback Spend by Year
Quest Diagnostics Buyback Spend 2025: $450.00M
Quest Diagnostics buyback spend in 2025 was $450.00M, surged 198.0% from 2024.
Quest Diagnostics Buyback Spend 2024: $151.00M
Quest Diagnostics buyback spend in 2024 was $151.00M, plunged 45.1% below 2023.
Quest Diagnostics Buyback Spend 2023: $275.00M
Quest Diagnostics buyback spend in 2023 was $275.00M, plunged 80.5% below 2022.
Quest Diagnostics Buyback Spend 2022: $1.41B
Quest Diagnostics buyback spend in 2022 was $1.41B, plunged 36.0% below 2021.
Quest Diagnostics Buyback Spend 2021: $2.20B
Quest Diagnostics buyback spend in 2021 was $2.20B.
See more financial history for Quest Diagnostics (DGX).
Sector peers — Buyback Spend
Companies in the same sector as Quest Diagnostics, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $5.54B | Healthcare |
| Merck & Co., Inc. (MRK) | $5.08B | Healthcare |
| Eli Lilly and Company (LLY) | $4.11B | Healthcare |
| Novo Nordisk A/S (NVO) | $1.39B | Healthcare |
| AbbVie Inc. (ABBV) | $980.00M | Healthcare |
| AstraZeneca PLC (AZN) | $719.66M | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
Frequently asked questions
What is Quest Diagnostics's buyback spend?
Latest reported buyback spend for Quest Diagnostics (DGX) is $450.00M (period ending March 31, 2026).
How has Quest Diagnostics buyback spend changed year-over-year?
Quest Diagnostics (DGX) buyback spend changed +198.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Quest Diagnostics buyback spend?
Quest Diagnostics (DGX) buyback spend compound annual growth rate is +6.7% over the most recent 5 years available.
When did Quest Diagnostics buyback spend hit its highest annual value?
Quest Diagnostics buyback spend reached its highest annual value of $2.20B in 2021.
What was Quest Diagnostics buyback spend in 2024?
Quest Diagnostics (DGX) buyback spend in 2024 was $151.00M.
What was Quest Diagnostics buyback spend in 2025?
Quest Diagnostics (DGX) buyback spend in 2025 was $450.00M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
DGX Overview
Company profile, financial tools, and key metrics
DGX Revenue Counter
Earns $357.62 every second. See per minute, hour, and day.
DGX Earnings Counter
Earns $32.47 per second net profit. See per minute, hour, and day.
DGX Economic Scale
Exceeds Monaco's GDP. Compare with world economies.
DGX What If Invested
What if you had invested $1,000? See historical returns from any date.
DGX How It Makes Money
Discover visual breakdown of $11.28B in revenue — where it comes from and where it goes.
DGX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DGX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DGX Daily Price Character
Steady · 50.6% historical win rate (green days). Streaks & record days.
DGX Buybacks
2.09% TTM buyback yield. Shareholder yield & SBC comparison.
DGX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
DGX Dividend Profile
Yield: 1.72%. Safety: 5/8. See full history.
DGX Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
DGX Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.